614TiPUCGI 28 Panirinox: A randomized phase II study assessing Panitumumab + FOLFIRINOX or mFOLFOX6 in RAS and BRAF wild type metastatic colorectal cancer patients (mCRC) selected from circulating DNA analysis. (23rd October 2018) - Mazard, T; Ghiringhelli, F; Mollevi, C; Assenat, E; Gavoille, C; Smith, D; Pezzella, V; Meddeb, R; Pastor, B; Ychou, M; Thierry, A R